New cancer drugs pose challenge for rheumatologists

Rheumatologists should be prepared for more presentations of rheumatic disease triggered by new immune checkpoint inhibitors for cancer, say US researchers.

They identified 13 patients who presented at the Johns Hopkins Rheumatology clinic with rheumatological symptoms after taking ipilimumab and nivolumab for solid tumours.

Nine developed inflammatory arthritis, four with synvotis confirmed